SensoDetect (SDET) Q1 2026 earnings summary

Executive summary

• Q1 2026 marked by board changes, strengthened governance, and a strategic shift toward scalable, screening-based solutions and international expansion, especially in the Middle East.

• Commercial focus increased, with new partnerships and prioritization of projects with higher market potential.

• Transitioned to consolidated group reporting from Q3 2025, now including subsidiaries in Hong Kong and China.

Financial highlights

• Net sales for Q1 2026 were 1,303 KSEK, mainly from royalty income in China.

• Net result after financial items was -1,861 KSEK; EPS was approximately -0.004 SEK.

• Cash flow from operating activities was -466 KSEK; cash and cash equivalents at period end were 632 KSEK.

• Equity ratio as of March 31, 2026, was 71%.

Outlook and guidance

• Focus remains on international commercialization, recurring revenue models, and operational efficiency.

• Certain R&D activities, such as the ASD study in Saudi Arabia, are paused to prioritize scalable ADHD screening solutions.

• Ongoing evaluation of financial structure and potential balance sheet measures.